530 results match your criteria Urticaria Cholinergic


Acetylcholine-induced whealing in cholinergic urticaria - What does it tell us?

J Dermatol Sci 2021 May 7. Epub 2021 May 7.

Dermatological Allergology, Allergie-Centrum-Charité, Dpt. of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. Electronic address:

Background: Cholinergic urticaria (CholU) is characterized by the occurrence of itchy wheals induced by sweating. Intradermal injections of acetylcholine (ACh) have been proposed to help with diagnosing CholU and subgrouping of patients, but controlled studies are largely missing.

Objective: To compare the rates of positive ACh test results in well characterized CholU patients and controls and to identify clinical features of CholU linked to ACh reactivity. Read More

View Article and Full-Text PDF

Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria.

Mil Med 2021 Apr 14. Epub 2021 Apr 14.

Department of Allergy and Immunology, Walter Reed National Military Medical Center, Bethesda, MD 20892, USA.

Cholinergic urticaria is a common disorder that has been associated with anaphylaxis. We report the events, workup, and eventual second dose vaccination of a patient at the Walter Reed National Military Medical Center, who had immediate anaphylaxis after administration of the first Pfizer-BioNTech Covid-19 (BNT162b2) vaccine dose. During the initial evaluation after anaphylaxis, the patient described a history of symptoms suspicious for cholinergic urticaria but had never had this condition confirmed with standardized testing. Read More

View Article and Full-Text PDF

Clinical Characteristics, Management, and Natural History of Chronic Inducible Urticaria in a Pediatric Cohort.

Int Arch Allergy Immunol 2021 Apr 1:1-8. Epub 2021 Apr 1.

Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Center, Montreal, Québec, Canada.

Background: Some forms of chronic urticaria (CU) can be specifically attributed to a response to a definite trigger, referred to as chronic inducible urticaria (CIndU). We aimed to assess the demographics, clinical characteristics, comorbidities, natural history, and management of pediatric patients with CIndU.

Methods: Over a 6-year period, children presenting to the allergy clinic at the Montreal Children's Hospital (MCH) with CIndU were prospectively recruited. Read More

View Article and Full-Text PDF

Comparative Efficacy of Fexofenadine Versus Levocetrizine Versus Desloratadine via 1% Histamine Wheal Suppression Test.

Kathmandu Univ Med J (KUMJ) 2020 Jan.-Mar;18(69):19-22

Department of Dermatology, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.

Background Urticaria and allergic dermatoses remains a great challenge to treating dermatologist. Histamine is the major mediator in such disorders. Antihistamines as levocetrizine, fexofenadine and desloratadine are often used to treat such conditions. Read More

View Article and Full-Text PDF
February 2021

Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses.

BMC Vet Res 2020 Oct 1;16(1):368. Epub 2020 Oct 1.

K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California-Davis, CA, 95616, Davis, USA.

Background: Meperidine is a synthetic opioid that belongs to the phenylpiperidine class and is a weak mu receptor agonist. In horses there are a limited number of published studies describing the analgesic effects of systemically administered meperidine in horses. The objective of this study was to describe the pharmacokinetics, behavioral and physiologic effects and effect on thermal threshold of three doses of intravenously administered meperidine to horses. Read More

View Article and Full-Text PDF
October 2020

Chronic inducible urticaria: classification and prominent features of physical and non-physical types.

Acta Dermatovenerol Alp Pannonica Adriat 2020 Sep;29(3):141-148

Clinical Department of Dermatovenereology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.

Chronic inducible urticaria (CIndU) is a common inflammatory skin condition characterized by the recurrence of itchy wheals and/or angioedema that lasts more than 6 weeks and is induced by specific physical or environmental stimuli (cold, heat, exercise, pressure, sunlight, vibration, water, etc.). According to the current international classification, it includes physical urticarias (dermographism, delayed-pressure urticaria, exercise-induced urticaria, cold urticaria, heat urticaria, solar urticaria, and vibratory urticaria) and non-physical urticarias caused by exposure to specific stimuli (cholinergic urticaria, contact urticaria, and aquagenic urticaria). Read More

View Article and Full-Text PDF
September 2020

[Treatment of simultaneously occurring urticaria and atopic dermatitis with dupilumab].

Hautarzt 2021 Mar;72(3):249-251

Dermatologische Praxis Dr. Herbst & Kollegen, Rheinstr. 7-9, 64283, Darmstadt, Deutschland.

Our 21-year-old woman presented with symptoms of chronic spontaneous urticaria with angioedema and of cholinergic urticaria as well as of atopic dermatitis. Treatment with the IgE antibody omalizumab resulted in an improvement of urticaria; however, relapses of the atopic dermatitis occurred. The use of the monoclonal IL-4/13 receptor antibody dupilumab resulted in complete healing of the atopic dermatitis, complete remission of the chronic spontaneous urticaria with angioedema, and the satisfactory control of cholinergic flare ups over a follow-up period of 26 weeks. Read More

View Article and Full-Text PDF

Chronic inducible urticaria subtypes in children: Clinical features and prognosis.

Pediatr Allergy Immunol 2021 01 24;32(1):146-152. Epub 2020 Aug 24.

Department of Pediatric Allergy, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Background: Chronic inducible urticaria (CIndU) is a subtype of chronic urticaria induced by a physical stimulus.

Objective: To evaluate the clinical features, prognostic factors, and natural course of childhood CIndU subtypes.

Methods: Patients (1-18 years old, n = 117) diagnosed with CIndU between March 2011 and March 2019 were analyzed. Read More

View Article and Full-Text PDF
January 2021

Chronic inducible urticaria: confirmation through challenge tests and response to treatment.

Einstein (Sao Paulo) 2020 10;18:eAO5175. Epub 2020 Jul 10.

Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Objective To evaluate the positivity of challenge tests of patients suspected of chronic inducible urticaria and the response to treatment. Methods A retrospective study of electronic medical records of patients suspected of chronic inducible urticaria. All patients were submitted to challenge tests with triggering stimuli, according to the clinical history and, subsequently, the response to drug treatment was evaluated. Read More

View Article and Full-Text PDF

Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature.

Dermatol Ther 2020 11 11;33(6):e14010. Epub 2020 Aug 11.

Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

To examine the effectiveness of omalizumab on disease activity and quality of life in patients with cholinergic urticaria (CholU). Further, a systematic review of the literature was performed to identify all studies of use of omalizumab in CholU. A total of 23 patients (63. Read More

View Article and Full-Text PDF
November 2020

Omalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea.

Allergy Asthma Immunol Res 2020 Sep;12(5):894-896

Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.

View Article and Full-Text PDF
September 2020

Clinical Management of Exercise-Induced Anaphylaxis and Cholinergic Urticaria.

Authors:
Mario Geller

J Allergy Clin Immunol Pract 2020 Jul - Aug;8(7):2209-2214

Division of Medicine, Academy of Medicine of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address:

Exercising is both pleasant and healthy. In some individuals, it can trigger adverse reactions. Examples of these reactions include exercise-induced anaphylaxis (EIA) and cholinergic urticaria (ChoIU). Read More

View Article and Full-Text PDF

Cholinergic Urticaria: Clinical Presentation and Natural History in a Tropical Country.

Biomed Res Int 2020 24;2020:7301652. Epub 2020 May 24.

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Background: Cholinergic urticaria (CholU) is a subset of chronic inducible urticaria characterized by the recurrent pinpoint-sized wheals that are induced by exercising or increasing core body temperature. Currently, the data of CholU in tropical climate is still limited.

Objective: To investigate the clinical features and natural course of CholU in a tropical country. Read More

View Article and Full-Text PDF

Direct and indirect action modes of acetylcholine in cholinergic urticaria.

Authors:
Yoshiki Tokura

Allergol Int 2021 Jan 19;70(1):39-44. Epub 2020 Jun 19.

Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan. Electronic address:

Cholinergic urticaria (CholU) manifests small, itchy and/or painful wheals occurring upon perspiration and mechanically involving acetylcholine (Ach). Although a considerable number of studies have been conducted, the pathomechanisms underlying perspiration-associated release of histamine remain to be elucidated. We have proposed that CholU can be categorized into two major subtypes: Ach-indirectly induced, sweat allergic type and Ach-directly induced, depressed sweating type. Read More

View Article and Full-Text PDF
January 2021

Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients.

Clin Transl Allergy 2020 1;10:18. Epub 2020 Jun 1.

Department of Dermatology and Allergy, Allergie-Centrum-Charité/ECARF, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.

Background: Cholinergic urticaria (CholU) is a common type of chronic inducible urticaria, characterized by small itchy wheals that appear upon physical exercise or passive warming. , a skin resident fungus, has been identified as an antigen that induces mast cell/basophil degranulation and wheal formation through specific IgE, in Japanese patients with atopic dermatitis and CholU. In this study we aimed in assessing the rate of IgE sensitizations against skin resident fungi in European CholU patients. Read More

View Article and Full-Text PDF

Regular sweating activities for the treatment of cholinergic urticaria with or without acquired idiopathic generalized anhidrosis.

Dermatol Ther 2020 07 7;33(4):e13647. Epub 2020 Jun 7.

Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Cholinergic urticaria (CholU) decreases affected individuals' quality of life because they must avoid stimuli including exercise and hot bathing. Although case reports have indicated that regular sweating activities are effective for CholU with hypohidrosis, little evidence is available. This retrospective medical record review examined CholU patients who received any form of treatment at our hospital. Read More

View Article and Full-Text PDF

Anaphylactic Bronchospasm during Induction of General Anaesthesia: A Case Report.

JNMA J Nepal Med Assoc 2019 Jul-Aug;57(218):266-268

Department of Anaesthesia and Intensive Care, Kathmandu Medical College, Sinamangal, Kathmandu, Nepal.

Bronchospasm represents the clinical manifestation of bronchial muscles contraction resulting in reduced alveolar air flow. Non-allergic mechanisms or anaphylaxis underlie the genesis of perioperative bronchospasm, a potential anaesthetic disaster. Early recognition and treatment are crucial. Read More

View Article and Full-Text PDF

A visual analogue scale for itch and pain in 23 cases of cholinergic urticaria.

J Eur Acad Dermatol Venereol 2020 Sep 28;34(9):e493-e495. Epub 2020 May 28.

Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.

View Article and Full-Text PDF
September 2020

Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Int Arch Allergy Immunol 2020 30;181(5):321-333. Epub 2020 Mar 30.

Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

This update on chronic urticaria (CU) focuses on the prevalence and pathogenesis of chronic spontaneous urticaria (CSU), the expanding spectrum of patient-reported outcome measures (PROMs) for assessing CU disease activity, impact, and control, as well as future treatment options for CU. This update is needed, as several recently reported findings have led to significant advances in these areas. Some of these key discoveries were first presented at past meetings of the Collegium Internationale Allergologicum (CIA). Read More

View Article and Full-Text PDF
November 2020

Real-life treatment of patients with cholinergic urticaria in German-speaking countries.

J Dtsch Dermatol Ges 2019 11;17(11):1141-1147

Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Background: Cholinergic urticaria (CholU) is a frequent type of chronic inducible urticaria. Symptomatic treatment with second-generation antihistamines (sgAH) is recommended by current guidelines as first-line therapy, but little is known about how patients with CholU are treated in real life and how they respond to treatment.

Aim: To assess real-life treatment of CholU in German-speaking countries. Read More

View Article and Full-Text PDF
November 2019

Cholinergic synovitis: Description of four cases.

Reumatol Clin (Engl Ed) 2021 Feb 7;17(2):113-115. Epub 2019 Nov 7.

Servicio de Neurología, Hospital Universitario Ramón y Cajal, Madrid, España.

We present the clinical and ultrasound findings of four patients with moderate synovitis and urticarial skin lesions associated with sports activity in warm environments. We include progress after treatment with hydroxycin. We suggest a causal relationship similar to cholinergic urticaria where the neighbouring synovium responds with effusion that self-limits once the triggering process has been halted. Read More

View Article and Full-Text PDF
February 2021

Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.

J Dermatolog Treat 2021 Feb 12;32(1):19-28. Epub 2019 Nov 12.

Department of Medicine, Division of Dermatology, University of Arizona, Tucson, AZ, USA.

While dupilumab has emerged as an effective treatment for moderate-to-severe atopic dermatitis (AD) since its approval in 2017, interleukin-4 and 13 blockade has also demonstrated efficacy in off-label chronic dermatologic conditions. To identify chronic dermatologic conditions in which dupilumab has demonstrated efficacy. Thirty-three reports of dupilumab use in non-AD dermatologic conditions were identified through systematic literature review. Read More

View Article and Full-Text PDF
February 2021

Cholinergic urticaria with hypohidrosis successfully treated with omalizumab.

J Dermatol 2020 Feb 29;47(2):e47-e48. Epub 2019 Oct 29.

Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

View Article and Full-Text PDF
February 2020

PLAID syndrome: Characteristic presentation and a novel therapeutic option.

Pediatr Dermatol 2020 Jan 21;37(1):147-149. Epub 2019 Oct 21.

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.

PLCG2-associated antibody deficiency and immune dysregulation (PLAID) is an autosomal dominant inherited disease caused by genomic deletion in PLCG2 and is characterized by cold urticaria, humoral immune deficiency, cutaneous granulomas, and autoimmune disease. The patient described in this case had a typical presentation for a PLAID phenocopy and experienced intense pruritus, a common complication of PLAID, starting in early childhood. After trialing H1 and H2 blockers with no improvement, oral glycopyrrolate was used with near resolution of the patient's symptoms. Read More

View Article and Full-Text PDF
January 2020

Clinical utility of the basophil activation test in the diagnosis of sweat allergy.

Allergol Int 2020 Apr 12;69(2):261-267. Epub 2019 Oct 12.

Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.

Background: Many patients with atopic dermatitis and cholinergic urticaria display an immediate-type allergy to autologous sweat. Although the histamine release test (HRT) using semi-purified sweat antigen (QR) was available for the detection of immediate sweat allergy, the existence of HRT low responders could not be disregarded. Furthermore, it has not been established whether the results of the HRT are consistent with the autologous sweat skin test (ASwST). Read More

View Article and Full-Text PDF

[Meta-analysis of efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine in treatment of chronic urticarial].

Zhongguo Zhong Yao Za Zhi 2019 Aug;44(16):3551-3557

Department of Medicine,Hebei General Hospital Shijiazhuang 020051,China.

To analyze the efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine as well as desloratadine alone in the treatment of chronic urticaria by Meta-analysis,in order to provide evidence-based reference for clinical treatment.PubMed,CBM,Wan Fang,VIP database and CNKI database were retrieved to collect randomized controlled trials( RCT) about Tripterygium Glycosides Tablets combined with desloratadine( test group) as well as desloratadine alone( control group) in the treatment of chronic urticaria. Meta-analysis was performed by using Rev Man 5. Read More

View Article and Full-Text PDF

A case of cold-induced cholinergic urticaria accompanied by cholinergic urticaria showing a positive ice cube test.

Allergol Int 2020 Jan 23;69(1):150-151. Epub 2019 Aug 23.

Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.

View Article and Full-Text PDF
January 2020

Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria.

Pharmacogenomics J 2020 02 13;20(1):87-93. Epub 2019 Aug 13.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.

H1 nonsedating antihistamines, such as desloratadine, are first-line treatment options for chronic spontaneous urticaria (CSU). However, desloratadine induces various degrees of sedation side effect in CSU patients, and no biomarkers currently exist for predicting the severity of such side effect. Herein, we evaluated the association between HRH1 gene rs901865 polymorphism and the severity of sedation side effect following desloratadine therapy in patients with CSU. Read More

View Article and Full-Text PDF
February 2020

Life-Threatening Angioedema Following Varenicline Administration.

J Clin Psychopharmacol 2019 May/Jun;39(3):285-287

Department of Emergency Medicine, Lin-Kou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan and College of Medicine, Chang Gung University, Taoyuan, Taiwan School of Medicine, International Medical University, Kuala Lumpur, Malaysia and Sarawak General Hospital, Kuching, Sarawak, Malaysia Sarawak General Hospital, Kuching, Sarawak, Malaysia Department of Emergency Medicine, Lin-Kou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan and College of Medicine, Chang Gung University, Taoyuan, Taiwan

View Article and Full-Text PDF

Real-life experience in the treatment of solar urticaria: retrospective cohort study.

Clin Exp Dermatol 2019 Jul 13;44(5):e164-e170. Epub 2019 Apr 13.

Photodermatosis Service, Department of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.

Background: Solar urticaria (SU) is a rare photodermatosis causing a significant impact on patients' quality of life (QoL), and treatment is often challenging.

Aim: To analyse clinical experience with a tailored stepwise therapeutic approach.

Methods: A retrospective cohort design was used. Read More

View Article and Full-Text PDF